Chemoradiotherapy with CAPOX and SHR-1701 for unresectable gastric or GEJ cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this Phase 2 trial, patients with unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma receive radiotherapy plus CAPOX chemotherapy and the PD-L1/TGF-β bispecific antibody SHR-1701, followed by SHR-1701 maintenance as appropriate. The primary endpoint is progression-free survival, with secondary endpoints including response rate, overall survival, local control, surgical resection rates, pathological responses, safety, and quality of life. Exploratory analyses will look for biomarkers linked to response and survival. The study plans to enroll about 60 participants across multiple centers to evaluate whether this combination can improve outcomes over current first-line options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female participants aged 18 to 75 years.
2. Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
3. Unresectable locally advanced or metastatic gastric cancer, with primary and metastatic lesions amenable to radiotherapy (excluding patients with brain metastases or extensive metastatic disease).
4. HER2-negative disease.
5. ECOG performance status of 0-1.
6. At least one measurable lesion according to RECIST version 1.1.
7. Adequate organ function, including:

   * Hemoglobin ≥90 g/L;
   * White blood cell count ≥3.5 × 10⁹/L;
   * Absolute neutrophil count ≥1.5 × 10⁹/L;
   * Platelet count ≥100 × 10⁹/L;
   * Serum creatinine ≤1.0 × upper limit of normal (ULN);
   * Blood urea nitrogen (BUN) ≤1.0 × ULN;
   * Alanine aminotransferase (ALT) ≤1.5 × ULN;
   * Aspartate aminotransferase (AST) ≤1.5 × ULN;
   * Alkaline phosphatase (ALP) ≤1.5 × ULN;
   * Total bilirubin (TBIL) ≤1.5 × ULN;
   * Negative urine protein;
   * Normal coagulation function.
8. No contraindications to immunotherapy.
9. No history of hypersensitivity to fluoropyrimidines or platinum-based agents.
10. No prior surgery, chemotherapy, immunotherapy, or other antitumor therapy for gastric or gastroesophageal junction cancer since diagnosis.
11. No previous radiotherapy to the intended irradiation sites.
12. Ability to understand and willingness to sign a written informed consent form.

Exclusion Criteria:

1. Brain metastases or extensive metastatic disease.
2. Prior treatment with PD-1, PD-L1, TGF-β, CTLA-4 inhibitors, or other investigational immunotherapies.
3. Severe autoimmune diseases, including but not limited to active inflammatory bowel disease (Crohn's disease or ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, or autoimmune vasculitis (e.g., Wegener's granulomatosis).
4. Symptomatic interstitial lung disease or active infectious/non-infectious pneumonitis.
5. Conditions associated with an increased risk of gastrointestinal perforation, including active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis, or other known risk factors.
6. History of another malignancy, except adequately treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
7. Active infection, heart failure, myocardial infarction within 6 months, unstable angina, or unstable cardiac arrhythmia.
8. Any physical examination findings, laboratory abnormalities, or uncontrolled medical conditions that, in the investigator's judgment, may interfere with study outcomes or increase the risk of treatment-related complications.
9. Pregnant or breastfeeding women.
10. Congenital or acquired immunodeficiency, including HIV infection, or a history of organ transplantation or allogeneic hematopoietic stem cell transplantation.
11. Active hepatitis B infection (HBV DNA ≥2,000 IU/mL), active hepatitis C infection, or active tuberculosis.
12. Receipt of any live or other prohibited vaccines within 4 weeks before study treatment. Seasonal inactivated influenza vaccines are permitted, whereas intranasal live attenuated influenza vaccines are not permitted.
13. Concurrent treatment with other immunosuppressive agents, chemotherapy, investigational drugs, or long-term systemic corticosteroids.
14. Psychiatric disorders, substance abuse, or social conditions that may compromise treatment compliance, as determined by the investigator.
15. Known hypersensitivity or contraindication to any study treatment.

Where it's running

• Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting
• Shanxi Cancer Hospital
  Taiyuan, Shanxi, China Recruiting
• National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
  Beijing, China Recruiting

Study contacts

• Principal investigator: Jing Jin, M.D. — Chinese Academy of Medical Sciences
• Study coordinator: Jing Jin, M.D.
• Email: jinjing@csco.org.cn
• Phone: 15650735818

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHR-1701 plus rivoceranib (with or without SHR-2554) for advanced gastric and gastroesophageal junction adenocarcinoma after first-line immunotherapy

  This will see if combining SHR-1701 with rivoceranib, with or without SHR-2554, helps people with advanced gastric or gastroesophageal junction cancer whose disease progressed on or who couldn't tolerate first-line immunotherapy.

  Recruiting Phase 2 China Medical University, China · Shenyang, Liaoning · NCT07311408

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• TEAS after gastrectomy to aid recovery after laparoscopic stomach cancer surgery

  A randomized trial tests whether transcutaneous electrical acupoint stimulation (TEAS) after laparoscopic gastrectomy helps people recover faster and with less pain compared with a sham treatment.

  Recruiting at 8 sites The Affiliated Hospital of Qingdao University · Qingdao, Shandong and 7 other locations · NCT07898293

• Anti-PD-1 with chemotherapy and intraperitoneal nab-paclitaxel for untreated advanced gastric cancer with ascites

  This study tests whether adding anti-PD-1 therapy to standard chemotherapy plus intraperitoneal nab-paclitaxel can help patients with untreated advanced gastric cancer and malignant ascites.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07855640

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer

  Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.

  Recruiting Hebei Medical University · Shijiazhuang, None Selected · NCT07849608

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.